Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's
Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's
This study evaluates how effective a new formulation of a marketed drug is in increasing the
 time to onset of dyskinesia (abnormal twisting, writhing movements) in patients with
 Parkinson's Disease who have been taking levodopa for less than 2 years.
Inclusion Criteria:

 -  Must be on 600mg or less of levodopa therapy for two years or less.

 -  Must be on a stable dose of levodopa therapy for at least 4 weeks prior to screening.

 Exclusion Criteria:

 -  Current or past history of Dyskinesia.

 -  State of dementia or have a MMSE score < 26 at screening.